Cadinha & Co. LLC cut its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 86.2% during the second quarter, Holdings Channel reports. The fund owned 900 shares of the medical instruments supplier’s stock after selling 5,610 shares during the period. Cadinha & Co. LLC’s holdings in C.R. Bard were worth $284,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. SRS Capital Advisors Inc. increased its position in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. Creative Planning increased its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the last quarter. Blair William & Co. IL increased its position in C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after buying an additional 30 shares during the last quarter. First Merchants Corp increased its position in C.R. Bard by 0.6% in the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after buying an additional 32 shares during the last quarter. Finally, Pennsylvania Trust Co increased its position in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares during the last quarter. 85.32% of the stock is owned by hedge funds and other institutional investors.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 318.63 on Thursday. The firm’s 50-day moving average price is $318.77 and its 200-day moving average price is $282.55. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27. The firm has a market cap of $23.16 billion, a PE ratio of 41.83 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.54 earnings per share. Equities research analysts expect that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were issued a $0.26 dividend. The ex-dividend date was Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.67%.
ILLEGAL ACTIVITY NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2796902/c-r-bard-inc-bcr-shares-sold-by-cadinha-co-llc.html.
Several research firms recently weighed in on BCR. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a research note on Tuesday, June 13th. BMO Capital Markets downgraded C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price objective for the company. in a research note on Tuesday, April 25th. Morgan Stanley cut C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.